Can Airbnb really be worth more than Marriott?
Room-rental platform Airbnb ended its first day of trading at $144.70. That means it has a market cap of around $100bn, twice the value of Marriott, the largest hotel operator. Can that be possible?
Shares in home rental platform Airbnb “more than doubled” when the company started trading on the Nasdaq last week, says Dominic Rushe in The Guardian. Initially priced at $68 a share, the stock surged to more than $150 at one point, ending the first day of trading at $144.70.
This means that the company, founded in 2008 when the cofounders rented out air mattresses in their San Francisco apartments, is worth around $100bn, twice the value of Marriott, the largest hotel operator.
It’s no surprise that investors are bullish, says Jim Armitage in the Evening Standard. Airbnb may not “have the first clue about how to fold a doily”, but it does offer the “biggest, cheapest, perhaps quirkiest selection of rooms to sleep in across the world” and has used “brilliant technology” to do this “quickly and easily”. Even Covid-19 won’t hold it back. With “millions – perhaps hundreds of millions” of people “just desperate to travel”, demand “will bounce back like we’ve never seen before once the vaccines take hold”. What’s more, customers are likely to prefer somewhere “where as few people as possible have been congregating”.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Investors need to calm down, says Lex in the Financial Times. It’s true that travel trends “are on Airbnb’s side” amid “persistent wariness” over “crowded hotels and planes”. Still, remember that the company is currently losing money, which means that it will need to “keep a lid on costs” at the same time as it needs “outlandish growth” to justify its “lofty valuation”. As a result, “investors seeking a bargain should stay at home”.
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
Alex is an investment writer who has been contributing to MoneyWeek since 2015. He has been the magazine’s markets editor since 2019.
Alex has a passion for demystifying the often arcane world of finance for a general readership. While financial media tends to focus compulsively on the latest trend, the best opportunities can lie forgotten elsewhere.
He is especially interested in European equities – where his fluent French helps him to cover the continent’s largest bourse – and emerging markets, where his experience living in Beijing, and conversational Chinese, prove useful.
Hailing from Leeds, he studied Philosophy, Politics and Economics at the University of Oxford. He also holds a Master of Public Health from the University of Manchester.
-
Lifetime ISA reform: Retirement option could be scrapped in overhaulA consultation on a product replacing the Lifetime ISA is set to be launched this year, and the option to use it to save for retirement is expected to be axed in the shake-up
-
HMRC stamp duty crackdown sees probes of property deals jump 88% – what to watch out forFrom bogus stamp duty refund claims to misleading the taxman about who owns a property, HMRC is increasing its scrutiny of stamp duty land tax reporting. Here’s how.
-
Three promising emerging-market stocks to diversify your portfolioOpinion Omar Negyal, portfolio manager, JPMorgan Global Emerging Markets Income Trust, highlights three emerging-market stocks where he’d put his money
-
Coface offers excess profit in an unloved sectorCoface is a world leader in trade-credit insurance with key competitive advantages in a niche market
-
Exciting opportunities in biotechBiotech firms should profit from the ‘patent cliff’, which will force big pharmaceutical companies to innovate or make acquisitions
-
How to invest in the new breed of payment providersUpstart payment providers are taking the world by storm. It’s time for investors to buy in, says Rupert Hargreaves
-
What turns a stock market crash into a financial crisis?Opinion Professor Linda Yueh's popular book on major stock market crashes misses key lessons, says Max King
-
How to add cryptocurrency to your portfolioA new listing shows how bitcoin might add value to a portfolio if cryptocurrency keeps gaining acceptance, says Cris Sholto Heaton
-
Profit from pest control with Rentokil InitialRentokil Initial is set for global expansion and offers strong sales growth
-
Three funds to buy for capital growth and global incomeOpinion Three investment trusts with potential for capital growth, selected by Adam Norris, co-portfolio manager of the CT Global Managed Portfolio Trust